This organization files Form 990, which has no section for application policy. Its filings cannot say either way.
The latest filing we hold carries no statement about applications. That is not the same as closed: public-charity Form 990s have no field for it, and many foundations leave the section blank.
Grants paid by year
Total assets by year
Where the money went · FY2025
Form 990 splits expenses into program services, management and fundraising. The split is self-reported, and a grantmaker, a research institute and a direct-service nonprofit book the same work differently. A line the return does not carry reads "not available"; it is never counted as zero.
| Year | Form | Revenue | Expenses | Grants paid | Assets | Net assets |
|---|---|---|---|---|---|---|
| FY2025 | 990 | $4,449,969 | $5,723,050 | $3,441,620 | $6,202,847 | $5,143,288 |
| FY2024 | 990 | $5,010,088 | $5,075,041 | $2,820,170 | $7,031,609 | $6,100,736 |
| FY2023 | 990 | $4,849,523 | $4,951,075 | $2,905,436 | $6,837,500 | $5,813,538 |
| FY2022 | 990 | $4,349,128 | $4,273,754 | $2,765,732 | $5,857,840 | $5,603,674 |
| FY2021 | 990 | $4,333,926 | $4,055,107 | $2,667,666 | $6,651,091 | $6,249,465 |
Figures are as reported on the e-filed return, with no restatement. Fiscal years are the funder's own tax year, labelled by the calendar year the period ends in. A blank line means the return does not carry that figure; a real zero shows as $0. When an amended return replaces an original, every figure here uses the amended return. The original is not shown. Giving is what the funder actually paid out toward its charitable purpose in the year (qualifying distributions on Form 990-PF, charitable disbursements otherwise). Assets are what it holds; giving is what moves.
Recipient focus areas
Where recipients are
Based on the 96% of grant rows we could match to an organization record. The rest stay as reported. The IRS assigns the NTEE category when it grants exemption. It often reflects the original filing, not today's giving.
| Recipient | Purpose | Amount | Year | Source |
|---|---|---|---|---|
| H LEE MOFFIT CANCER CENTER AND RESEARCH INSTITUTE FOUNDATION INCTAMPA, FL | IN SUPPORT OF CLINICAL TRIALS CONDUCTED UNDER THE SUNSHINE PROJECT. | $1,370,000 | 2021 | |
Recipients are shown as the funder wrote them on the return. A recipient with a link was matched to an organization record; the rest stay as reported and are never guessed.
| THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITALDETROIT, MI |
| IN SUPPORT OF CLINICAL TRIALS CONDUCTED UNDER THE SUNSHINE PROJECT. |
| $992,092 |
| 2025 |
| H LEE MOFFIT CANCER CENTER AND RESEARCH INSTITUTE FOUNDATION INCTAMPA, FL | IN SUPPORT OF CLINICAL TRIALS CONDUCTED UNDER THE SUNSHINE PROJECT. | $850,000 | 2022 |
| ALBERT EINSTEIN COLLEGE OF MEDICINEBRONX, NY | FOR 43 CHALLENGE PROJECT - ENGINEERED DESTABILIZED AU RICH ELEMENTS OF C-MYC 3UTR AS THERAPEUTICS FOR C-MYC DRIVEN PEDIATRIC CANCERS AND ONE CARON META IN EWING SARCOMA TRIAL | $820,000 | 2024 |
| ALBERT EINSTEIN COLLEGE OF MEDICINEBRONX, NY | TWO RESEARCH STUDY GRANTS " TARGETING THE TUMOR MICROENVIRONMENT OF METASTASIS TO TREAT METASTATIC EWING SARCOMA AND"RE-PURPOSING HIV NUCLEOSIDE REVERSE TRANSCRIPTAS INHIBITORS FOR HIGH RISK NEROBLASTOME THERAPY" | $770,000 | 2023 |
| ALBERT EINSTEIN COLLEGE OF MEDICINEBRONX, NY | FOR 43 CHALLENGE PROJECT - ENGINEERED DESTABILIZED AU RICH ELEMENTS OF C-MYC 3UTR AS THERAPEUTICS FOR C-MYC DRIVEN PEDIATRIC CANCERS AND ONE CARON META IN EWING SARCOMA TRIAL | $713,110 | 2025 |
| PARATOPE BIO INCWILMINGTON, DE | IN SUPPORT OF CLINICAL TRIALS CONDUCTED UNDER THE SUNSHINE PROJECT. | $700,000 | 2023 |
| H LEE MOFFIT CANCER CENTER AND RESEARCH INSTITUTETAMPA, FL | IN SUPPORT OF CLINICAL TRIALS CONDUCTED UNDER THE SUNSHINE PROJECT. | $657,764 | 2025 |
| H LEE MOFFIT CANCER CENTER AND RESEARCH INSTITUTETAMPA, FL | IN SUPPORT OF CLINICAL TRIALS CONDUCTED UNDER THE SUNSHINE PROJECT. | $603,918 | 2024 |
| H LEE MOFFIT CANCER CENTER AND RESEARCH INSTITUTETAMPA, FL | IN SUPPORT OF CLINICAL TRIALS CONDUCTED UNDER THE SUNSHINE PROJECT. | $528,675 | 2022 |
| H LEE MOFFIT CANCER CENTER AND RESEARCH INSTITUTETAMPA, FL | IN SUPPORT OF CLINICAL TRIALS CONDUCTED UNDER THE SUNSHINE PROJECT. | $487,062 | 2023 |
| H LEE MOFFIT CANCER CENTER AND RESEARCH INSTITUTETAMPA, FL | IN SUPPORT OF CLINICAL TRIALS CONDUCTED UNDER THE SUNSHINE PROJECT. | $448,468 | 2021 |
| THE REGENTS OF THE UNIVERSITY OF CALIFORNIALOS ANGELES, CA | FOR 43 CHALLENGE PROJECT - TREATING LEPTOMENINGEAL SPREAD OF PEDIATRIC MEDULLOBLASTOMA WITH QUANTUM RADIOBIOLOGY | $400,000 | 2024 |
| THE REGENTS OF THE UNIVERSITY OF CALIFORNIALOS ANGELES, CA | IN SUPPORT OF CLINICAL TRIALS CONDUCTED UNDER THE SUNSHINE PROJECT. | $400,000 | 2023 |
| ALBERT EINSTEIN COLLEGE OF MEDICINEBRONX, NY | TWO RESEARCH STUDY GRANTS " TARGETING THE TUMOR MICROENVIRONMENT OF METASTASIS TO TREAT METASTATIC EWING SARCOMA AND"RE-PURPOSING HIV NUCLEOSIDE REVERSE TRANSCRIPTAS INHIBITORS FOR HIGH RISK NEROBLASTOME THERAPY" | $306,865 | 2021 |
| PARATOPE BIO INCWILMINGTON, DE | FOR 43 CHALLENGE PROJECT - HARNESSING THE POWER OF INNATE ANTIBODIES FOR NOVEL THERAPIES IN PEDIATRIC CANCER RESEARCH | $300,000 | 2024 |
| UNIVERSITY OF ALABAMATUSCALOOSA, AL | IN SUPPORT OF CLINICAL TRIALS CONDUCTED UNDER THE SUNSHINE PROJECT. | $200,000 | 2022 |
| THE REGENTS OF THE UNIVERSITY OF CALIFORNIALOS ANGELES, CA | FOR 43 CHALLENGE PROJECT - TREATING LEPTOMENINGEAL SPREAD OF PEDIATRIC MEDULLOBLASTOMA WITH QUANTUM RADIOBIOLOGY | $200,000 | 2025 |
| CLEVELAND CLINIC FOUNDATIONCLEVELAND, OH | IN SUPPORT OF CLINICAL TRIALS CONDUCTED UNDER THE SUNSHINE PROJECT. | $192,451 | 2025 |
| DUKE UNIVERSITYDURHAM, NC | IN SUPPORT OF CLINICAL TRIALS CONDUCTED UNDER THE SUNSHINE PROJECT. | $168,091 | 2022 |
| THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITALDETROIT, MI | IN SUPPORT OF CLINICAL TRIALS CONDUCTED UNDER THE SUNSHINE PROJECT. | $160,154 | 2024 |
| THE UNIVERSITY OF NORTH CARLINA AT CHAPEL HILLCHAPEL HILL, NC | IN SUPPORT OF CLINICAL TRIALS CONDUCTED UNDER THE SUNSHINE PROJECT. | $126,671 | 2022 |
| CHILDREN'S HOSPITAL OF COLORADO FOUNDATIONAURORA, CO | BIOMARKER TRIAL PILLAR PROJECT CONDUCTED UNDER THE SUNSHINE PROJECT | $126,526 | 2024 |
| CLEVELAND CLINIC FOUNDATIONCLEVELAND, OH | IN SUPPORT OF CLINICAL TRIALS CONDUCTED UNDER THE SUNSHINE PROJECT. | $124,880 | 2022 |
| CHILDREN'S HOSPITAL OF COLORADO FOUNDATIONAURORA, CO | IN SUPPORT OF CLINICAL TRIALS CONDUCTED UNDER THE SUNSHINE PROJECT. | $112,823 | 2022 |
Nearest by size, location and giving pattern in the database. Geography weighs heavily. Treat it as a starting list, not a ranking of fit.
Form 990 · FY2024 · period ending Jun 30, 2024IRS bulk XML
Filing id 202432969349301628
Form 990 · FY2023 · period ending Jun 30, 2023
Filing id 202312839349301101
Form 990 · FY2022 · period ending Jun 30, 2022
Filing id 202300599349301700
Form 990 · FY2021 · period ending Jun 30, 2021
Filing id 202142799349300639
Form 990 · FY2019 · period ending Jun 30, 2019
Filing id 201942889349300119
Form 990 · FY2018 · period ending Jun 30, 2018
Filing id 201842959349300204
Form 990 · FY2017 · period ending Jun 30, 2017
Filing id 201702709349300305
IRS filings are the source for every fact on this page. Nothing a model writes is ever a source; it can only point at a row here.